

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
59472-A-PCT-USSerial No.
10/049,893

SEP 25 2002
INFORMATION DISCLOSURE CITATION
Use several sheets if necessary)

Applicants
David Stern, et al.Filing Date
February 13, 2002

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
<i>JAE</i>	US 5 8 6 4 0 1 8	4/16/96	Morser et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation	
					Yes	No
<i>JAE</i> WO 9 7 3 9 1 2 5	10/23/97	Europe				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>JAE</i>	Akama, T. Keith, et al., "Amyloid β -peptide stimulates nitric oxide production in astrocytes through an NgkB-dependent mechanism," <u>Proc. Natl. Acad. Sci.</u> , 1998, 95: 5795-5800 (Exhibit 3);
	Behl, C., et al., "Hydrogen Peroxide Mediates Amyloid β Protein Toxicity", <u>Cell</u> , 1994, 77: 817-827 (Exhibit 4);
	Combs, K. Colin, et al. "Identification of Microglial Signal Transduction Pathways Mediating a Neurotoxic Response to Amyloidogenic Fragments of β -Amyloid and Prion Proteins", <u>Journal of Neuroscience</u> , 1999, 19(3): 928-939 (Exhibit 5);
	Forloni, Gianluigi, et al. "Amyloid in Alzheimer's Disease and Prior-Related Encephalopathies: Studies With Synthetic Peptides", <u>Progress in Neurobiology</u> , 1996, 49: 287-315 (Exhibit 6);
	Ghiso, Jorge, et al. "Unifying Features of Systemic and Cerebral Amyloidosis", <u>Molecular Neurobiology</u> , 1994, 8(1): 49-64 (Exhibit 7);
	Inagaki, Fuyuhiko, et al. "Conformation of Erabutoxins a and b in Aqueous Solution as Studied by Nuclear Magnetic Resonance and Circular Dichroism", 1978, 89: 433-443 (Exhibit 8); Need magazine article #26
	Kilsilevsky, Robert, et al. "Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease", <u>Nature Medicine</u> , 1995, 1: 143-148 (Exhibit 9);
	Kimball, M.R., et al. "Molecular Conformation of Erabutoxin b; Atomic Coordinates At 2.5 Å Resolution", <u>Biochemical and Biophysical Research Communication</u> , 1979, 88: 950-959 (Exhibit 10);
<i>JAE</i>	Kindy, S. Mark and Rader, J. Daniel "Reduction in Amyloid A Amyloid Formation in Apolipoprotein-E-Deficient Mice", <u>American J. Pathology</u> , 1998, 152: 1387-1395 (Exhibit 11);

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

DEC 10 2002

TECH CENTER 1600/2900

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Mark No.
59472-A-PCT-USSerial No.
10/049,893Applicants
David Stern, et al.Filing date
February 13, 2002

Group Art Unit

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Kirschner, A. Daniel, et al. "X-ray diffraction from intraneuronal pairs helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross- β conformation", Proc. National Acad. Sci., 1986, 83: 503-507 (Exhibit 12);

Lander, H. L., et al. "Activation of the Receptor for Advanced Glycation Endproducts triggers a MAP Kinase pathway regulated by oxidant stress", J. Biol. Chem., 1997, 272: 17810-17814 (Exhibit 13);

Levine, Harry "Thioflavine T interaction with synthetic Alzheimer's disease β -amyloid peptides: Detection of amyloid aggregation in solution", Protein Sci., 1993, 2(3): 404-410 (Exhibit 14);

Mattson, M.P. and Goodman, Y. "Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium", Brain Res., 1995, 676: 219-224 (Exhibit 15);

Pike, J. Christian, et al. "Neurodegeneration Induced by β -Amyloid Peptides in vitro: The Role of Peptide Assembly State", J. Neuroscience., 1993, 13(4): 1676-1687 (Exhibit 16);

Prusiner, B. Stanley, et al. "Prion Protein Biology", Cell, 1998, 93: 337-348 (Exhibit 17);

Serpell, L.C., et al. "The molecular basis of amyloidosis", Cellular and Molecular Life Sci., 1997, 53: 871-887 (Exhibit 18);

Sipe, D. Jean, et al.) "Characterization of the Inbred CE/J Mouse Strain as Amyloid Resistant", Am. J. of Pathology, 1993, 143: 1480-1485 (Exhibit 19);

Sipe, D. Jean "Amyloidosis", Ann. Review of Bioche., 1992, 61: 947-975 (Exhibit 20);

Smith, M.A. et al. "Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's Disease", Am. J. Pathol., 1994, 145(1): 42-47 (Exhibit 21);

Soto, Claudio and Castano, M. Eduardo "The conformation of Alzheimer's β peptide determines the rate of amyloid formation and its resistance to proteolysis", Biochemical J., 1996, 314: 701-707 (Exhibit 22);

Soto, Claudio, et al. "Apolipoprotein E increases the fibrillogenic potential of synthetic peptides derived from Alzheimer's, Gelsolin and AA amyloids", 1995, FEBS Letters, 1995, 371: 110-114 (Exhibit 23);

Strauss, Sylvia, et al. "Detection of Interleukin-6 and α_2 -Macroglobulin Immunoreactivity in Cortex and Hippocampus of Alzheimer's Disease Patients", J. Acad. of Pathology., 1992, 66(2): 223-230 (Exhibit 24);

Yan S-D, Chen X, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern DM, Schmidt "A-M: RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease", Nature, 1996, 382: 685-691 (Exhibit 25);

Yan, Shi Du, et al. "Amyloid- β peptide-Receptor for Advanced Glycation End product interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease", Proceedings of the Nat. Acad. Sci., 1997, 94: 5296-5301 (Exhibit 26); and

Yankner, A. Bruce "Mechanisms of Neuronal Degeneration in Alzheimer's Disease", Neuron, 1996, 16: 921-932 (Exhibit 27).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

DEC 10 2002

TECH CENTER 1600/2900

Form PTO-1449 MAY 13 2005 U.S. Department of Commerce
Patent and Trademark Office

Application Number	10/049,893
Filing Date	July 22, 2002
First Named Inventor	David Stern, et al.
Art Unit	
Examiner Name	
Attorney Docket No.	59472-A-PCT- US/JPW/AJM/JCS

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document

FOREIGN PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
<i>HE</i>		WO 99/18987	4/22/1999	The Trustees of Columbia University in the City of New York	
<i>J</i>		WO 97/26913	7/31/1997	The Trustees of Columbia University in the City of New York	
<i>J</i>		WO 95/20979	8/10/1995	The Picower Institute for Medical Research	

EXAMINER
SIGNATURE

DATE CONSIDERED


Gregory K. Smith 1/25/2006

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English Language Translation is attached.

Applicants: Stern, et al.
Serial No. : 10/049,893
Filed: July 22, 2002
Exhibit 1

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	10/049,893
	Filing Date	July 22, 2002
	First Named Inventor	David Stern, et al.
	Art Unit	
	Examiner Name	
Attorney Docket No.		59472-A-PCT-US/JPW/AJM/JCS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		February 21, 2005 Communication enclosing a Supplementary Partial European Search Report issued in connection with related European Patent Application No. 00955464.3, on behalf of The Trustees of Columbia University in the City of New York, regional stage of PCT International Application No. PCT/US00/22059, filed August 11, 2000	
		Zhu, et al., "RAGE interaction with Abeta fibrils activates signal transduction mechanisms and results in apoptosis activation of MAP kinases and nuclear translocation of NF-EkB," Society for Neuroscience Abstracts 24: 228 (1998)	
		Yan, et al., "RAGE and Amyloid-Beta Peptide Neurotoxicity in Alzheimer's Disease," Nature: 382: 685-691 (1996)	
		Yan, et al., "Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide," Biochimica Et Biophysica Acta. Molecular Basis of Disease 1502: 145-157 (2000)	
		Yan, et al., "Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis," Nature Medicine 6: 643-651 (2000)	
		Sousa, et al., "Interaction of the receptor for advanced glycation endproducts (RAGE) with transthyretin triggers nuclear transcription factor kB (NF0kB) activation," Laboratory Investigation 80: 1101-1110 (2000)	

 EXAMINER
SIGNATURE

DATE CONSIDERED

1/25/2006

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.